Lipocine (LPCN) Other Non-Current Liabilities (2012 - 2024)
Lipocine's (LPCN) quarterly Other Non-Current Liabilities came in at $3586.0 in Q3 2024, down 87.82% YoY from $29440.0 in Q4 2023, and down 97.47% on a QoQ basis from $141668.0 in Q2 2024.
Lipocine (LPCN) Other Non-Current Liabilities (2012 - 2024) Analysis & Trends
Lipocine (LPCN) has 7 years of Other Non-Current Liabilities data on file, last reported at $3586.0 in Q3 2024.
- Quarterly Other Non-Current Liabilities fell 87.82% year-over-year to $3586.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $3586.0 (down 87.82% YoY) and the FY2023 annual result came in at $17166.0, down 92.53% from the prior year.
- Other Non-Current Liabilities retreated to $3586.0 in Q3 2024, from $141668.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $47.0 million in Q2 2021 to a low of $3586.0 in Q3 2024.
- A 5-year average of $14.8 million and a median of $840336.0 in 2021 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities surged 4942.43% — and 2023, when it sank 99.91%.
- Tracing LPCN's Other Non-Current Liabilities over 5 years: stood at $20.0 million in 2020, then plunged by 96.02% to $795796.0 in 2021, then plunged by 71.12% to $229856.0 in 2022, then sank by 92.53% to $17166.0 in 2023, then plunged by 79.11% to $3586.0 in 2024.
- The last three Other Non-Current Liabilities figures came in at $3586.0 (Q3 2024), $141668.0 (Q2 2024), and $57238.0 (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 3,586.00 |
| Jun 30, 2024 | 141,668.00 |
| Mar 31, 2024 | 57,238.00 |
| Dec 31, 2023 | 17,166.00 |
| Sep 30, 2023 | 29,440.00 |
| Jun 30, 2023 | 104,267.00 |
| Mar 31, 2023 | 131,722.00 |
| Dec 31, 2022 | 229,856.00 |
| Sep 30, 2022 | 33.99 Mn |
| Jun 30, 2022 | 37.76 Mn |
| Mar 31, 2022 | 42.37 Mn |
| Dec 31, 2021 | 795,796.00 |
| Sep 30, 2021 | 38.87 Mn |
| Jun 30, 2021 | 46.98 Mn |
| Mar 31, 2021 | 840,336.00 |
| Dec 31, 2020 | 20.02 Mn |
| Sep 30, 2020 | 19.61 Mn |
| Jun 30, 2020 | 19.69 Mn |
| Mar 31, 2020 | 20.45 Mn |
| Dec 31, 2019 | 17.85 Mn |